MEK is a promising target in the basal subtype of bladder cancer

Oncotarget
Nathan M MerrillMatthew B Soellner

Abstract

While many resources exist for the drug screening of bladder cancer cell lines in 2D culture, it is widely recognized that screening in 3D culture is more representative of in vivo response. Importantly, signaling changes between 2D and 3D culture can result in changes to drug response. To address the need for 3D drug screening of bladder cancer cell lines, we screened 17 bladder cancer cell lines using a library of 652 investigational small-molecules and 3 clinically relevant drug combinations in 3D cell culture. Our goal was to identify compounds and classes of compounds with efficacy in bladder cancer. Utilizing established genomic and transcriptomic data for these bladder cancer cell lines, we correlated the genomic molecular parameters with drug response, to identify potentially novel groups of tumors that are vulnerable to specific drugs or classes of drugs. Importantly, we demonstrate that MEK inhibitors are a promising targeted therapy for the basal subtype of bladder cancer, and our data indicate that drug screening of 3D cultures provides an important resource for hypothesis generation.

References

Feb 1, 1985·The Journal of Clinical Investigation·S SetoD A Carson
Jul 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P SagasterH Ludwig
Jan 19, 2007·International Journal of Cancer. Journal International Du Cancer·Jose A KaramJer-Tsong Hsieh
Apr 25, 2007·Molecular Carcinogenesis·Magdalena ZietarskaAnne-Marie Mes-Masson
Feb 15, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J E RosenbergUNKNOWN Cancer and Leukemia Group B
Feb 19, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jinhai FanJer-Tsong Hsieh
May 6, 2008·Tissue Engineering. Part B, Reviews·Jungwoo LeeNicholas A Kotov
Jan 13, 2009·Gynecologic Oncology·Kristy ShieldGregory E Rice
Apr 6, 2011·Leukemia & Lymphoma·James B Johnston
Mar 10, 2012·BMC Cancer·Benjamin BlaserOlivier Dormond
Aug 15, 2012·Nature Reviews. Urology·Philip Levy HoKeith Syson Chan
Jan 21, 2014·Cancer Chemotherapy and Pharmacology·Pasquale CironeCedo M Bagi
Jan 31, 2014·Nature·UNKNOWN Cancer Genome Atlas Research Network
Feb 13, 2014·Proceedings of the National Academy of Sciences of the United States of America·Jeffrey S DamrauerWilliam Y Kim
May 17, 2014·Assay and Drug Development Technologies·Rasheena EdmondsonLiju Yang
Jul 11, 2014·Science Translational Medicine·Sandra RebouissouFrançois Radvanyi
Mar 15, 2015·International Journal of Molecular Sciences·Delphine AntoniGeorges Noel
May 1, 2015·Neoplasia : an International Journal for Oncology Research·Daniel H HovelsonScott A Tomlins
Sep 26, 2015·International Journal of Molecular Sciences·Sally TemrazAli Shamseddine
Nov 7, 2015·Oncotarget·Michael K KiesslingGerhard Rogler
Nov 17, 2015·Nature·UNKNOWN Cancer Cell Line Encyclopedia Consortium, UNKNOWN Genomics of Drug Sensitivity in Cancer Consortium
Jan 17, 2016·Molecular Cancer Therapeutics·Maria PinkerneilGuenter Niegisch
Jan 28, 2016·Translational Andrology and Urology·Isuru S JayaratnaColin P N Dinney
May 14, 2016·Mini Reviews in Medicinal Chemistry·Martin Boegemann, Laura-Maria Krabbe
Aug 16, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shu-Xiong ZengChong-Xian Pan

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT00087295
NCT02465060

Software Mentioned

Morpheus
DSS
GraphPad Prism
Rstudio
R

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.